Guided Bone RegenerationNCT07367464
Assessment Of Guided Bone Regeneration Using Xenograft Mixed With Allogenic Bone Graft Versus Xenograft Mixed With Autogenous Graft For Augmentation Of Maxillary Alveolar Ridges
A study testing Allogenic bone graft mixed with Xenograft in ratio 1:1 and Autologous bone graft mixed with Xenograft in ratio 1:1 in people with Guided Bone Regeneration, run by Cairo University at 1 site in Egypt.
Trial summary
This study aims to evaluate the effect of Allogenic bone graft mixed with Xenograft in ratio 1:1, on the radiographic and histomorphometric assessment versus Autologous bone graft mixed with Xenograft in ratio 1:1 in maxillary deficient ridges، In guided bone regeneration of deficient edentulous maxillary ridges, will… Read more about this study
- Who is it for?
- Ages 20 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Guided Bone Regeneration
- What is being tested?
- Allogenic bone graft mixed with Xenograft in ratio 1:1 and Autologous bone graft mixed with Xenograft in ratio 1:1
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jun 2024to 1 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 20-50 years.
- Totally or partially edentulous maxillary ridges.
- Patients with insufficient bone for an implant placement.
- Residual alveolar width ranging from 2 to 4 mm.
- Minimum of 10 mm vertical dimension to nasal floor or sinus floor.
- Patients with healthy systemic condition (Medically free).
- Adequate inter-arch space for placement of the implant prosthetic part.
Who cannot join
- Pathological lesions in the defect site.
- Systemic diseases that would interfere with bone metabolism. Uncontrolled diabetic patients.
- Ongoing treatment or a history of recent chemotherapy or radiotherapy.
- Patient with medical condition that contraindicates surgical procedures.
- Patients on medication that may interfere with healing (Corticosteroids, Bisphosphonate, Chemo/radio therapy).
- Patients with vertical bone deficiency.
- Patients with habits that may jeopardize the implant longevity and affect the results of the study such as alcoholism or para-functional habits.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Radiographic And Histomorphometric Assessment Of Guided Bone Regeneration Using Xenograft Mixed With Allogenic Bone Graft Versus Xenograft Mixed With Autogenous Bone Graft For Augmentation Of Deficient Maxillary Alveolar Ridges A Randomized Clinical Trial
This study aims to evaluate the effect of Allogenic bone graft mixed with Xenograft in ratio 1:1, on the radiographic and histomorphometric assessment versus Autologous bone graft mixed with Xenograft in ratio 1:1 in maxillary deficient ridges، In guided bone regeneration of deficient edentulous maxillary ridges, will the application of Xenograft mixed with Allograft (1:1) be as effective as Xenograft mixed with Autogenous graft (1:1) in terms of dimensional ridge changes and Quality of newly formed bone?
Evaluation of the patient's general condition of the oral cavity, to make sure it complies with the criteria required to be enrolled in the study in terms of oral hygiene and pathological conditions.
Read more
A full thickness flap will be elevated with two releasing incisions, decortication of the buccal aspect of the ridge, placing of grafting material which will be covered by collagen pericardium membranes, tacks placement at the labial side to fix the membrane in place, horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures for closure.
Intervention group: will be filled with mixture of Xenogenic graft and the Allogenic bone graft chips.
Control group: will be filled with mixture of Xenogenic graft and Autogenous bone particulate harvested either the ramus.
For both groups, All the subjects will be taking CBCT at pre surgical and 6 months post surgical. outcomes : Bucco-Palatal horizontal bone gain, Alveolar ridge height, Percentage of new vital bone formation and Percentage of residual bone graft 6 months post-surgical.
Read the detailed description
This study aims to evaluate the effect of Allogenic bone graft mixed with Xenograft in ratio 1:1, on the radiographic and histomorphometric assessment versus Autologous bone graft mixed with Xenograft in ratio 1:1 in maxillary deficient ridges. Null hypothesis: no significant difference in ridge dimensional changes is expected to occur on comparing Xenograft mixed with Allograft versus Xenografts mixed with autogenous bone grafts in guided bone regeneration.
The study will be conducted at the post-graduate clinic of the periodontology and Oral Implantology Departments, Faculty of Dentistry, Cairo University, Egypt. Patients will be selected from the outpatient clinic of the Department of Oral Implantology, Cairo University.
- Clinical examination \& informed consent: Evaluation of the patient's general condition of the oral cavity, to make sure it complies with the criteria required to be enrolled in the study in terms of oral hygiene and pathological conditions.
- Radiographic examination: Preoperative cone beam computed tomography (CBCT) will be done to exclude any pathosis and measure the bone width of the deficient area. Bone width will be measured from the reformatted cross-sectional image of the CBCT 2.0 mm below the tip of the crest at every single deficient site taking a specific anatomical landmark in the opposing teeth as a reference point for the measurements taking into consideration that the patients are biting in maximum intercuspation. The average of these measurements will be calculated to be a representative value of the preoperative width for each case from the preoperative CBCT. Immediate and 6 months postoperative CBCT will be done with the patients biting in maximum intercuspation and the same measurements will be taken from the same reference areas that were previously selected from the preoperative scan. Alveolar height will be measured from crest of the ridge to the nasal floor or sinus floor.
- Surgical procedures: Local anesthesia will be administered by infiltration or nerve block to achieve the necessary anesthesia and guided bone regeneration will be done according to the allocation concealment.All procedures will be performed by the same surgeon.As a prophylactic measure all patients will receive 2 g of V-penicillin amoxicillin/clavulanate 2 g for 10 days starting 1 hour pre-operatively or Clindamycin 300 mg for 10 days in event of penicillin allergy. A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site. vertical incisions at the canine eminence will be avoided and instead extended distal to the canine to avoid future dehiscence at this site. The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. Control group (Xenograft + Autogenous bone) Autogenous bone particulate will be harvested either from the mandibular ramus. Mandibular ramus as a donor site: A submarginal incision will be placed within the keratinized mucosa opposite to the lower first molar and extending 1 cm along the ramus of the mandible. Autogenous bone will be harvested by an Auto-chip maker (ACM) bur and the harvested Autogenous bone chips is then to be mixed in equal ratio 1:1 volume with Xenograft of particle size 0.25-1 mm and will be added to the harvested autogenous bone to create 1:1 composite graft. Intervention group (Xenograft + Allograft) Xenogenic graft is then to be mixed in equal 1:1 volume of particles size 0.25-1 mm with the Allogenic bone graft chips 0.25-1mm to create 1:1 composite graft. The recipient site will be debrided from any soft tissue or periosteum remnants. The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site. All grafts will be covered by a collagen pericardium bio-resorbable membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. Additional particulate will be packed under the membrane laterally to over fill the site. With bone tack pin fixation at both lingual and buccal sides. The particulate composite graft will be packed onto the defect and overfilling will be done to compensate for future resorption.The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. Follow-up protocol will be done every other day for the first week, weekly for the first month, and then monthly for 3 months. Postoperative CBCT scans will be done for all patients at 6 months interval, to assess the amount of horizontal bone gain which is the primary outcome.
- Second stage surgery: After 6 months, re-entry will be done utilizing a full thickness mucoperiosteal flap, and a core biopsy will be taken using a 2 mm trephine bur from the pre-planned implant positions in the direction of the implant osteotomy for histomorphometric analysis of the augmented bone to measure the bone area percent which is the secondary outcome. Dental implants with diameters ranging 3.7 to 4.2 mm will be inserted in the augmented ridge in a 2-stage procedure according to the manufacturer's protocol. Cover screws will be placed, and the flaps will be adapted with resorbable 4-0 sutures.
- Histomorphometric and statistical analysis: The core biopsies will be sectioned and stained with H\&E stain for examination under a light microscope with a ×50 magnification. Bone volume will be measured for each specimen and the mean volume for native bone and newly formed bone will be calculated for statistics.Quantitative histomorphometric analysis will be performed by OLYMPUS Stream software. Data management and statistics will be done by using the Statistical Package for Social Sciences version 22.
- Postoperative instructions and follow up: Antibiotics (Amoxicillin 1g twice daily for 5 days) to prevent postoperative infection.Anti-inflammatory drugs (NSAIDS; Ibuprofen 600mg three times daily for 5 days) to avoid edema, pain or swelling.Antiseptic mouth rinse (0.12% Chlorhexidine oral rinse will be prescribed for 60 seconds two times a day for 14 days.
- Patient self-care instructions:
Patients will be instructed to apply an ice bag to the treated area for the first 24 hours and avoid any brushing and trauma to the surgical site for one week.
- Conditions
- Guided Bone Regeneration
- Being tested
- Allogenic bone graft mixed with Xenograft in ratio 1:1, Autologous bone graft mixed with Xenograft in ratio 1:1
- Keywords
- Guided Bone Regeneration, DFDBA, Autogenous Bone Graft, Xenograft, Xenograft Mixed With Autogenous Bone Graft, Xenograft Mixed With Allogenic Bone Graft, Deficient Maxillary Alveolar Ridges
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allogenic bone graft mixed with Xenograft in ratio 1:1Biological
Xenogenic graft is then to be mixed in equal 1:1 volume of particles size 0.25-1 mm with the Allogenic bone graft chips to create 1:1 composite graft.
Autologous bone graft mixed with Xenograft in ratio 1:1Biological
Autogenous bone particulate will be harvested from the mandibular ramus. Mandibular ramus as a donor site: A submarginal incision will be placed within the keratinized mucosa opposite to the lower first molar and extending 1 cm along the ramus of the mandible.
| Study group | Role | What they receive |
|---|---|---|
| Allogenic bone graft mixed with Xenograft in ratio 1:1 | Experimental | A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site.The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. recipient site will be debrided from any soft tissue or periosteum remnants.The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site then it will be covered by a collagen pericardium membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. Receives: Biological: Allogenic bone graft mixed with Xenograft in ratio 1:1 |
| Autologous bone graft mixed with Xenograft in ratio 1:1 | Active comparator | A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site.The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. recipient site will be debrided from any soft tissue or periosteum remnants.The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site then it will be covered by a collagen pericardium membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. Receives: Biological: Autologous bone graft mixed with Xenograft in ratio 1:1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bucco-Palatal horizontal bone gain
Bone width will be measured from the reformatted cross-sectional image of the CBCT 2 mm below the tip of the crest at every single deficient site taking a specific anatomical landmark in the opposing teeth as a reference point for the measurements taking into consideration that the patients are biting in maximum intercuspation. The average of these measurements will be calculated to be a representative value of the preoperative width for each case from the preoperative CBCT. Immediate and 6 months postoperative CBCT will be done while the patients are also biting in maximum intercuspation and the same measurements will be taken from the same reference areas previously selected from the preoperative scan.
Measured: 6 months postoperatively
Secondary outcomes (3)
Alveolar ridge height:
It will be measured from the crest of the ridge to the nasal floor or sinus floor.
Measured: 6 months postoperatively
Percentage of new vital bone formation
core biopsies will be preserved in a 10% formalin solution. Following that, they will undergo four weeks of EDTA decalcification. The specimens will be treated and embedded in paraffin after decalcification to generate tissue blocks. The paraffin blocks will be split into longitudinal sections of 5m thickness. For histological examination and histomorphometric analysis, these slices will be stained with hematoxylin and eosin (H\&E) or Masson's trichromatic (MT) stains. A digital light microscope will be used to photograph the stained sections.
Histomorphometric analysis will be undertaken to determine the percentage of the total analysed histological area occupied by bone, graft particles, and soft tissue stroma using (Leica QWin 500 image analysis software, Leica Microsystems, Switzerland).
Measured: 6 months postoperatively
Percentage of residual bone graft
core biopsies will be preserved in a 10% formalin solution. Following that, they will undergo four weeks of EDTA decalcification. The specimens will be treated and embedded in paraffin after decalcification to generate tissue blocks. The paraffin blocks will be split into longitudinal sections of 5m thickness. For histological examination and histomorphometric analysis, these slices will be stained with hematoxylin and eosin (H\&E) or Masson's trichromatic (MT) stains. A digital light microscope will be used to photograph the stained sections. Histomorphometric analysis will be undertaken to determine the percentage of the total analysed histological area occupied by bone, graft particles, and soft tissue stroma using (Leica QWin 500 image analysis software, Leica Microsystems, Switzerland).
Measured: 6 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start1 Jun 2024
- Primary completion1 Dec 2025
- Study completion1 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Guided Bone RegenerationStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abdulnaser Abousetta, Cairo University
- Investigators
- Mohamed A. Abousetta, Bachelor, Principal investigator, Cairo UniversityMohamed M. Shaker, Professor, Study chair, Cairo UniversityWeam A. El-Battawy, Ass. Prof., Study director, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07367464
- Sponsor's protocol ID
- 23-5-24
- Status last verified
- Apr 2026
- First submitted
- 14 Jan 2026
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiographic And Histomorphometric Assessment Of Guided Bone Regeneration Using Xenograft Mixed With Allogenic Bone Graft Versus Xenograft Mixed With Autogenous Bone Graft For Augmentation Of Deficient Maxillary Alveolar Ridges A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07367464
- Acronym / sponsor ID
- 23-5-24
- Conditions
- Guided Bone Regeneration
- Keywords
- Guided Bone Regeneration, DFDBA, Autogenous Bone Graft, Xenograft, Xenograft Mixed With Autogenous Bone Graft, Xenograft Mixed With Allogenic Bone Graft, Deficient Maxillary Alveolar Ridges
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Jun 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of Allogenic bone graft mixed with Xenograft in ratio 1:1, on the radiographic and histomorphometric assessment versus Autologous bone graft mixed with Xenograft in ratio 1:1 in maxillary deficient ridges، In guided bone regeneration of deficient edentulous maxillary ridges, will the application of Xenograft mixed with Allograft (1:1) be as effective as Xenograft mixed with Autogenous graft (1:1) in terms of dimensional ridge changes and Quality of newly formed bone?
Evaluation of the patient's general condition of the oral cavity, to make sure it complies with the criteria required to be enrolled in the study in terms of oral hygiene and pathological conditions.
A full thickness flap will be elevated with two releasing incisions, decortication of the buccal aspect of the ridge, placing of grafting material which will be covered by collagen pericardium membranes, tacks placement at the labial side to fix the membrane in place, horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures for closure.
Intervention group: will be filled with mixture of Xenogenic graft and the Allogenic bone graft chips.
Control group: will be filled with mixture of Xenogenic graft and Autogenous bone particulate harvested either the ramus.
For both groups, All the subjects will be taking CBCT at pre surgical and 6 months post surgical. outcomes : Bucco-Palatal horizontal bone gain, Alveolar ridge height, Percentage of new vital bone formation and Percentage of residual bone graft 6 months post-surgical.
Detailed description
This study aims to evaluate the effect of Allogenic bone graft mixed with Xenograft in ratio 1:1, on the radiographic and histomorphometric assessment versus Autologous bone graft mixed with Xenograft in ratio 1:1 in maxillary deficient ridges. Null hypothesis: no significant difference in ridge dimensional changes is expected to occur on comparing Xenograft mixed with Allograft versus Xenografts mixed with autogenous bone grafts in guided bone regeneration.
The study will be conducted at the post-graduate clinic of the periodontology and Oral Implantology Departments, Faculty of Dentistry, Cairo University, Egypt. Patients will be selected from the outpatient clinic of the Department of Oral Implantology, Cairo University.
- Clinical examination \& informed consent: Evaluation of the patient's general condition of the oral cavity, to make sure it complies with the criteria required to be enrolled in the study in terms of oral hygiene and pathological conditions.
- Radiographic examination: Preoperative cone beam computed tomography (CBCT) will be done to exclude any pathosis and measure the bone width of the deficient area. Bone width will be measured from the reformatted cross-sectional image of the CBCT 2.0 mm below the tip of the crest at every single deficient site taking a specific anatomical landmark in the opposing teeth as a reference point for the measurements taking into consideration that the patients are biting in maximum intercuspation. The average of these measurements will be calculated to be a representative value of the preoperative width for each case from the preoperative CBCT. Immediate and 6 months postoperative CBCT will be done with the patients biting in maximum intercuspation and the same measurements will be taken from the same reference areas that were previously selected from the preoperative scan. Alveolar height will be measured from crest of the ridge to the nasal floor or sinus floor.
- Surgical procedures: Local anesthesia will be administered by infiltration or nerve block to achieve the necessary anesthesia and guided bone regeneration will be done according to the allocation concealment.All procedures will be performed by the same surgeon.As a prophylactic measure all patients will receive 2 g of V-penicillin amoxicillin/clavulanate 2 g for 10 days starting 1 hour pre-operatively or Clindamycin 300 mg for 10 days in event of penicillin allergy. A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site. vertical incisions at the canine eminence will be avoided and instead extended distal to the canine to avoid future dehiscence at this site. The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. Control group (Xenograft + Autogenous bone) Autogenous bone particulate will be harvested either from the mandibular ramus. Mandibular ramus as a donor site: A submarginal incision will be placed within the keratinized mucosa opposite to the lower first molar and extending 1 cm along the ramus of the mandible. Autogenous bone will be harvested by an Auto-chip maker (ACM) bur and the harvested Autogenous bone chips is then to be mixed in equal ratio 1:1 volume with Xenograft of particle size 0.25-1 mm and will be added to the harvested autogenous bone to create 1:1 composite graft. Intervention group (Xenograft + Allograft) Xenogenic graft is then to be mixed in equal 1:1 volume of particles size 0.25-1 mm with the Allogenic bone graft chips 0.25-1mm to create 1:1 composite graft. The recipient site will be debrided from any soft tissue or periosteum remnants. The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site. All grafts will be covered by a collagen pericardium bio-resorbable membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. Additional particulate will be packed under the membrane laterally to over fill the site. With bone tack pin fixation at both lingual and buccal sides. The particulate composite graft will be packed onto the defect and overfilling will be done to compensate for future resorption.The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. Follow-up protocol will be done every other day for the first week, weekly for the first month, and then monthly for 3 months. Postoperative CBCT scans will be done for all patients at 6 months interval, to assess the amount of horizontal bone gain which is the primary outcome.
- Second stage surgery: After 6 months, re-entry will be done utilizing a full thickness mucoperiosteal flap, and a core biopsy will be taken using a 2 mm trephine bur from the pre-planned implant positions in the direction of the implant osteotomy for histomorphometric analysis of the augmented bone to measure the bone area percent which is the secondary outcome. Dental implants with diameters ranging 3.7 to 4.2 mm will be inserted in the augmented ridge in a 2-stage procedure according to the manufacturer's protocol. Cover screws will be placed, and the flaps will be adapted with resorbable 4-0 sutures.
- Histomorphometric and statistical analysis: The core biopsies will be sectioned and stained with H\&E stain for examination under a light microscope with a ×50 magnification. Bone volume will be measured for each specimen and the mean volume for native bone and newly formed bone will be calculated for statistics.Quantitative histomorphometric analysis will be performed by OLYMPUS Stream software. Data management and statistics will be done by using the Statistical Package for Social Sciences version 22.
- Postoperative instructions and follow up: Antibiotics (Amoxicillin 1g twice daily for 5 days) to prevent postoperative infection.Anti-inflammatory drugs (NSAIDS; Ibuprofen 600mg three times daily for 5 days) to avoid edema, pain or swelling.Antiseptic mouth rinse (0.12% Chlorhexidine oral rinse will be prescribed for 60 seconds two times a day for 14 days.
- Patient self-care instructions:
Patients will be instructed to apply an ice bag to the treated area for the first 24 hours and avoid any brushing and trauma to the surgical site for one week.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Allogenic bone graft mixed with Xenograft in ratio 1:1 | Experimental | Biological: Allogenic bone graft mixed with Xenograft in ratio 1:1A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site.The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. recipient site will be debrided from any soft tissue or periosteum remnants.The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site then it will be covered by a collagen pericardium membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. |
| Autologous bone graft mixed with Xenograft in ratio 1:1 | Active comparator | Biological: Autologous bone graft mixed with Xenograft in ratio 1:1A full thickness flap will be elevated with two releasing incisions extending at least just distal to each tooth adjacent to the defect site.The flap will be reflected adequately to expose the defect. The cortical bone will be perforated with a small round bur to perform decortication of the buccal aspect of the ridge. recipient site will be debrided from any soft tissue or periosteum remnants.The grafts will be placed on the buccal aspect of the alveolar ridge, layer by layer, gently pressed to the recipient site then it will be covered by a collagen pericardium membranes. The membrane will be stretched tightly over the graft and titanium tacks will be placed at the labial side to fix the membrane in place. The incisions will be carefully closed with horizontal mattress sutures as well as single interrupted and continuous with resorbable sutures. |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Age: 20-50 years.
- Totally or partially edentulous maxillary ridges.
- Patients with insufficient bone for an implant placement.
- Residual alveolar width ranging from 2 to 4 mm.
- Minimum of 10 mm vertical dimension to nasal floor or sinus floor.
Key exclusion criteria (7 listed)
- Pathological lesions in the defect site.
- Systemic diseases that would interfere with bone metabolism. Uncontrolled diabetic patients.
- Ongoing treatment or a history of recent chemotherapy or radiotherapy.
- Patient with medical condition that contraindicates surgical procedures.
- Patients on medication that may interfere with healing (Corticosteroids, Bisphosphonate, Chemo/radio therapy).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allogenic bone graft mixed with Xenograft in ratio 1:1Xenogenic graft is then to be mixed in equal 1:1 volume of particles size 0.25-1 mm with the Allogenic bone graft chips to create 1:1 composite graft. | Biological | Allogenic bone graft mixed with Xenograft in ratio 1:1 |
| Autologous bone graft mixed with Xenograft in ratio 1:1Autogenous bone particulate will be harvested from the mandibular ramus. Mandibular ramus as a donor site: A submarginal incision will be placed within the keratinized mucosa opposite to the lower first molar and extending 1 cm along the ramus of the mandible. | Biological | Autologous bone graft mixed with Xenograft in ratio 1:1 |
Primary outcome
Bucco-Palatal horizontal bone gain
Time frame: 6 months postoperatively
Bone width will be measured from the reformatted cross-sectional image of the CBCT 2 mm below the tip of the crest at every single deficient site taking a specific anatomical landmark in the opposing teeth as a reference point for the measurements taking into consideration that the patients are biting in maximum intercuspation. The average of these measurements will be calculated to be a representative value of the preoperative width for each case from the preoperative CBCT. Immediate and 6 months postoperative CBCT will be done while the patients are also biting in maximum intercuspation and the same measurements will be taken from the same reference areas previously selected from the preoperative scan.
3 secondary outcomes
Alveolar ridge height:
Time frame: 6 months postoperatively
Percentage of new vital bone formation
Time frame: 6 months postoperatively
Percentage of residual bone graft
Time frame: 6 months postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
Related trials for Guided Bone Regeneration
Active, not recruiting
L-PRF Block vs Composite Graft for Horizontal Ridge Augmentation
Alveolar Ridge Resorption After Extraction, Alveolar Bone Loss
Not yet recruiting
Clinical Efficacy Assessment of Digitally Fabricated PEEK Barrier Membranes for Guided Bone Regeneration in Severe Bone Defects
Guided Bone Regeneration
Not yet recruitingObservational study
Impact of Gingival Phenotype on Guided Bone Regeneration in the Maxillary Anterior Region
Guided Bone Regeneration
Active, not recruitingObservational study
Evaluation of Bone Regeneration Outcomes Following Guided Bone Regeneration in the Anterior Maxillary Region
Implant Placement in Maxillary Esthetic Zone
Active, not recruitingObservational study
Long-Term Stability of Soft and Hard Tissues After Guided Bone Regeneration in the Maxillary Anterior Region
Alveolar Bone Deficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohamed A. Abousetta, Bachelor principal investigator
Cairo University
Mohamed M. Shaker, Professor study chair
Cairo University
Weam A. El-Battawy, Ass. Prof. study director
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Allogenic bone graft mixed with Xenograft in ratio 1:1 and Autologous bone graft mixed with Xenograft in ratio 1:1 in people with Guided Bone Regeneration, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed A. Abousetta (+201044276208, mohamed.abousetta@dentistry.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bucco-Palatal horizontal bone gain (time frame: 6 months postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.